Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD44 | P16070 | 1/20 | 0.46 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.38 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.38 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.38 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.38 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.38 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.38 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | RAPGEF4 | Q8WZA2 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.33 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | GPR3 | P46089 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8860053 | 0.89 | CD44 (0.46) | CD44GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL7062222 | 0.86 | CD44 (0.48) | CD44GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL13973185 | 0.86 | CD44 (0.36) | CD44CYP3A4RAPGEF4PTGS2GPR3 | |
| SCHEMBL6951667 | 0.83 | RAPGEF4 (0.38) | CD44CYP3A4LMNARAPGEF4SMN1; SMN2 | |
| SCHEMBL762587 | 0.83 | KDM1A (0.39) | CD44CYP3A4LMNARAPGEF4SMN1; SMN2 | |
| SCHEMBL7550920 | 0.83 | CD44 (0.46) | CD44GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL11043190 | 0.83 | CD44 (0.46) | CD44GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL120848 | 0.82 | CD44 (0.61) | CD44GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL261036 | 0.82 | ACHE (0.42) | CYP3A4RAPGEF4ALDH1A1PTGS2GPR3 | |
| SCHEMBL3874093 | 0.80 | RAPGEF4 (0.39) | CD44CYP3A4LMNARAPGEF4SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 163 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024026433-A2 | NOVEL DPP1 INHIBITORS AND USES THEREOF | INSMED INCORPORATED (US) | 2024-02-01 | — | — | WO | disclosed |
| US-20230046859-A1 | Bicyclic Compounds and their Uses | NOVARTIS PHARMA AG (CH) | 2023-02-16 | — | — | US | disclosed |
| EP-3854782-A1 | SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | Genentech, Inc. (US) | 2021-07-28 | — | — | EP | disclosed |
| WO-2020228685-A9 | FLUORINE-CONTAINING COMPOUND AND ANTI-CANCER MEDICAL USE THEREOF | 深圳艾欣达伟医药科技有限公司 | 2021-02-18 | — | — | WO | disclosed |
| WO-2020228685-A1 | FLUORINE-CONTAINING COMPOUND AND ANTI-CANCER MEDICAL USE THEREOF | 深圳艾欣达伟医药科技有限公司 | 2020-11-19 | — | — | WO | disclosed |
| US-10676669-B2 | Compound having naphthalene ring, liquid crystal composition and liquid crystal display device | JNC CORPORATION (JP) | 2020-06-09 | — | — | US | disclosed |
| US-10654808-B2 | Tyrosine kinase inhibitor and pharmaceutical composition comprising same | Guangdong Raynovent Biotech Co., Ltd. (CN) | 2020-05-19 | — | — | US | disclosed |
| WO-2020012357-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | INTEGRAL BIOSCIENCES PVT. LTD. (IN) | 2020-01-16 | — | — | WO | disclosed |
| EP-2987790-B1 | LIQUID CRYSTAL COMPOUND HAVING XANTHENE SKELETON AND EXHIBITING NEGATIVE DIELECTRIC ANISOTROPY, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY ELEMENT | JNC CORP (JP) | 2019-08-28 | — | — | EP | disclosed |
| US-10358602-B2 | Liquid crystal compound having polyfluoro-2-butenoxy group, liquid crystal composition and liquid crystal display device | JNC CORPORATION (JP) | 2019-07-23 | — | — | US | disclosed |
| US-7435455-B2 | Dihydrocoumarin derivative, liquid crystal composition containing the same, and liquid crystal display device | CHISSO CORPORATION (JP) | 2008-10-14 | — | — | US | disclosed |
| US-20080214545-A1 | Substituted Pyrazolyl Urea Derivatives Useful in the Treatment of Cancer | BAYER HEALTHCARE LLC | 2008-09-04 | — | — | US | disclosed |
| US-20080214545-A1 | Substituted Pyrazolyl Urea Derivatives Useful in the Treatment of Cancer | BAYER HEALTHCARE LLC | 2008-09-04 | — | — | US | disclosed |
| US-20080194597-A1 | Asulfonyl(urea, thiourea, guanidine, cyanoguanidine) compounds; cardiovascular disorders; thrombosis | PORTOLA PHARMACEUTICALS, INC. (US) | 2008-08-14 | — | — | US | disclosed |
| US-20080194597-A1 | Asulfonyl(urea, thiourea, guanidine, cyanoguanidine) compounds; cardiovascular disorders; thrombosis | PORTOLA PHARMACEUTICALS, INC. (US) | 2008-08-14 | — | — | US | disclosed |
| US-7358257-B2 | sulfonylurea derivatives, sulfonylthiourea derivatives, sulfonylguanidine derivatives, sulfonylcyanoguanidine derivatives, thioacylsulfonamide derivatives, and acylsulfonamide derivatives; effective for prevention and treatment of cardiovascular diseases, antithrombotic agents | PORTOLA PHARMACEUTICALS, INC. (US) | 2008-04-15 | — | — | US | disclosed |
| US-7358257-B2 | sulfonylurea derivatives, sulfonylthiourea derivatives, sulfonylguanidine derivatives, sulfonylcyanoguanidine derivatives, thioacylsulfonamide derivatives, and acylsulfonamide derivatives; effective for prevention and treatment of cardiovascular diseases, antithrombotic agents | PORTOLA PHARMACEUTICALS, INC. (US) | 2008-04-15 | — | — | US | disclosed |
| EP-1762605-A1 | Naphthalene compound with terminal hydrogen, liquid crystal composition including the compound, and LCD device including the liquid crystal composition | Chisso Petrochemial Corporation (JP) | 2007-03-14 | — | — | EP | disclosed |
| US-20070051919-A1 | NAPHTHALENE COMPOUND WITH TERMINAL HYDROGEN, LIQUID CRYSTAL COMPOSITION INCLUDING THE COMPOUND, AND LCD DEVICE INCLUDING THE LIQUID CRYSTAL COMPOSITION | CHISSO PETROCHEMICAL CORPORATION (JP) | 2007-03-08 | — | — | US | disclosed |
| US-20070051919-A1 | NAPHTHALENE COMPOUND WITH TERMINAL HYDROGEN, LIQUID CRYSTAL COMPOSITION INCLUDING THE COMPOUND, AND LCD DEVICE INCLUDING THE LIQUID CRYSTAL COMPOSITION | CHISSO PETROCHEMICAL CORPORATION (JP) | 2007-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070051919-A1 | NAPHTHALENE COMPOUND WITH TERMINAL HYDROGEN, LIQUID CRYSTAL COMPOSITION INCLUDING THE COMPOUND, AND LCD DEVICE INCLUDING THE LIQUID CRYSTAL COMPOSITION | LEF1, CFD, FOXO1 | CD44 4517/4885GRIN2D 1126/4885GRIN3B 4418/4885 |
| US-10654808-B2 | Tyrosine kinase inhibitor and pharmaceutical composition comprising same | ABL1, LCK, ERBB2 | CD44 2314/4885GRIN2D 3947/4885GRIN3B 2180/4885 |
| US-20080194597-A1 | Asulfonyl(urea, thiourea, guanidine, cyanoguanidine) compounds; cardiovascular disorders; thrombosis | PIGS, GP6, ASGR1 | CD44 3257/4885GRIN2D 3579/4885GRIN3B 3041/4885 |
| US-20080214545-A1 | Substituted Pyrazolyl Urea Derivatives Useful in the Treatment of Cancer | UMPS, SLC14A1, TP53 | CD44 3247/4885GRIN2D 4791/4885GRIN3B 4383/4885 |
| US-20230046859-A1 | Bicyclic Compounds and their Uses | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, C1R, F12 | CD44 4766/4885GRIN2D 1425/4885GRIN3B 2526/4885 |
| US-10676669-B2 | Compound having naphthalene ring, liquid crystal composition and liquid crystal display device | PYM1, CXCR1, CPNE4 | CD44 4792/4885GRIN2D 1341/4885GRIN3B 4459/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.